Allergan profit falls as Botox sales slump
Thursday, 28 April, 2005
Drugmaker Allergan said quarterly net earnings fell slightly, and sales of Botox missed analyst forecasts, sending shares down 2 per cent.
First-quarter profit was US$79.9 million, or 60 cents per share, compared with $80.8 million or 60 cents per share a year earlier.
Net sales rose to $527 million, from $472 million in the year earlier period.
Botox sales were $176 million, about $10 million short of analyst views.
Elevated blood protein levels predict mortality
Proteins that play key roles in the development of diseases such as cancer and inflammation may...
The microbiome helps to fight melanoma
Molecules produced by gut bacteria upon digestion of dietary fibre can improve the function of...
Heart implant brings hope to refractory angina patients
The coronary sinus reducer is understood to redistribute blood flow within the wall of the heart,...
